BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Company update

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.

Related news

IOVAIovance Biotherapeutics, Inc.2026-08-06 11:01 EST

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

IOVAIovance Biotherapeutics, Inc.2026-10-01 11:00 EST

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

View all latest news

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

IOVAIovance Biotherapeutics, Inc.2026-10-01 11:00 EST

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

IOVAIovance Biotherapeutics, Inc.2026-09-29 11:00 EST

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

IOVAIovance Biotherapeutics, Inc.2026-09-18 21:10 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVAIovance Biotherapeutics, Inc.2026-09-04 12:00 EST

Iovance Biotherapeutics to Present at Upcoming Conferences

IOVAIovance Biotherapeutics, Inc.2026-08-21 21:15 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Stock data

Close
14.23 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States